Cancer is a major cause of morbidity and mortality, with an estimated burden of 18.1 million new cases and 9.6 million cancer-related deaths in 2018 (WHO, International Agency for Research on Cancer, September 12th, 2018). Although new therapies have seen substantial success in treatment of cancer, difficult issues remain, such as the development of resistance mechanisms, off-target cytotoxicity and lack of efficacy.
OncoOne aims to perform first class drug development, to generate novel and highly potent therapeutics to treat underserved patients suffering from solid cancers and thus contribute to the global combat against cancer.
OncoOne does not anticipate to directly market final drug products. We will license drug candidates to pharmaceutical companies to take advantage of well-established production processes and commercialization routes. Revenues will be invested in future research projects.
We will apply state-of-the-art technologies and the highest possible quality standards to establish a successful and continuously researching life science company.
Our Founders & Management Board.
OncoOne was founded in June 2018 by Randolf Kerschbaumer, Michael Thiele, and Alexander Schinagl. The founders have a long history in industrial drug development and oncology research. Each member of the management team has successfully contributed to the development of GMP grade drug substances, patents and scientific publications. Our management team unites experience in science management, leading networks of innovation by external collaborations and performing first-class in-house laboratory work.
Randolf Kerschbaumer, PhD
Founder & Chief Executive Officer
Randolf has more than 20 years of experience in academic and big pharma R&D and acquired detailed knowledge of the entire drug development process, from early drug screening to clinical development. Randolf received a PhD in Biotechnology from the Vienna University of Natural Resources and Life Sciences (BOKU). He started his professional career at Baxter BioScience and held various senior leading positions in research and development of therapeutics in the areas of cancer, inflammation and hematologic disorders. Most recently he was leading the Oncology Research department at Shire. In addition, he is teaching “Industrial Drug Development” at the University of Natural Resources and Life Sciences (BOKU), Vienna.
Randolf leverages the knowledge and excellence of individuals and institutions regionally and globally to optimize first class drug development. His intellectual curiosity, love for science and strong entrepreneurial personality enables Randolf to link science with corporate strategies.
Michael Thiele, PhD
Founder & Chief Operating Officer
Michael is a renowned expert in immunology, tumor biology, biomarker and the development of biologics. Michael obtained his PhD in Biology at the Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen, Germany and started his professional career at Baxter BioScience. During his career at Baxter, Baxalta and Shire, Michael was leading a network of innovation with contract research organizations (CROs), key opinion leaders and academic institutions, which led to the discovery of new therapeutic targets. Before founding OncoOne Michael was heading the Department of Cell Biology in Oncology Research, R&D, at Shire.
His strong expertise in oncology and connection to an international scientific network enables Michael to provide the professional excellence to establish and coordinate a strong alliance of experts. He is eager to develop innovative cancer therapeutics in a flexible and highly professional environment.
Alexander Schinagl, PhD
Founder & Chief Scientific Officer
Alexander has a broad knowledge in molecular biology, biochemistry and cell biology techniques in the field of oncology and inflammation. Alexander received a PhD in Biotechnology from the Vienna University of Natural Resources and Life Sciences (BOKU) in an industrial collaboration with Baxter and Baxalta Innovations GmbH. Alexander started his career as master student at Baxter BioScience in 2009 and was focusing on assay design for drug characterization. As Supervisor, Alexander was leading and training laboratory technicians in a biosafety regulated environment in the department of Oncology Research.
Alexander´s passion for science, creativity and attention to details enables him to link scientific innovation with drug development. He is highly excited to explore novel cancer therapeutics in a flexible and creative environment.
Our team of scientists and researchers is highly committed to our goal of developing breakthrough cancer therapeutics. As our company continues to grow, we are looking for individuals with a passion for science who want to achieve something extraordinary. In this respect, we are delighted that Carina Hasenöhrl and Gregor Rossmüller are part of the team.